Indian shares opened on a buoyant note on Monday, with easing oil prices and renewed buying from foreign institutional investors amid concerns over the outlook for AI trade elsewhere globally helping underpin investor sentiment. The 30-share BSE Sensex was up 995 points, or 1.3 percent, at 75,450...
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.